The non-late breaking abstracts for next month’s American Society of Hematology meeting were released on Thursday, giving a peek into what will be some of the most heavily scrutinized data in San Diego in early December.
Below are a handful of the most notable:
Brukinsa still outperforming Imbruvica in CLL:…
Click here to view original post
